Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
Charpentier
B
B
Service de Néphrologie C.H.U. de Bicêtre, Kremlin Bicêtre, France.
Thervet
E
E
D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D000077561:Daclizumab; D004311:Double-Blind Method; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D010919:Placebos; D014019:Tissue Donors
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D010919:Placebos; D016572:Cyclosporine; D000077561:Daclizumab